EPW
ALNY icon

Evolve Private Wealth’s Alnylam Pharmaceuticals ALNY Stock Holding History

Evolve Private Wealth’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$266K Sell
882
-218
-20% -$65.8K 0.02% 785
2026
Q1 		$364K Sell
1,100
-683
-38% -$232K 0.02% 706
2025
Q4 		$709K Buy
+1,783
New +$789K 0.04% 402

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Evolve Private Wealth's ALNY Position: Q2 2026 in Review

Evolve Private Wealth reduced its Alnylam Pharmaceuticals (ALNY) stake by 20% in Q2 2026, selling an estimated $65.8K and leaving 882 shares worth $266K. The position accounts for 0.02% of the portfolio, ranked #785.

Evolve Private Wealth first reported a position in ALNY in Q4 2025 and has held it in 3 quarters since. The position peaked at $709K in Q4 2025. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Evolve Private Wealth held 882 shares of Alnylam Pharmaceuticals worth $266K as of Q2 2026.
  • Evolve Private Wealth sold 218 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $65.8K.
  • Alnylam Pharmaceuticals made up 0.02% of Evolve Private Wealth's portfolio in Q2 2026, its #785 holding.
  • Evolve Private Wealth first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Evolve Private Wealth's Alnylam Pharmaceuticals position peaked at $709K in Q4 2025.
  • 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Evolve Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.